(Q37972665)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Transforming growth factor-β/Smad signalling in diabetic nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Hui Yao Lan

series ordinal

1

1 reference

26 August 2017

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Pharmacology and Physiology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

731-738

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

Diabetic nephropathy: mechanisms of renal disease progression

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Diabetic nephropathy: important pathophysiologic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Transforming growth factor beta contributes to progressive diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Latency, activation, and binding proteins of TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Transcriptional control by the TGF-beta/Smad signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

TGF-beta signal transduction and mesangial cell fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Role of TGF-beta signaling in extracellular matrix production under high glucose conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Transforming growth factor-beta and Smad signalling in kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Transforming growth factor-β and Smads

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Essential role of Smad3 in angiotensin II-induced vascular fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Mechanism of chronic aristolochic acid nephropathy: role of Smad3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

BCL-2: pro-or anti-oxidant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Endothelial factors and diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad7 as a therapeutic agent for chronic kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Latent TGF-beta1 protects against crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Diabetes complications: the microRNA perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

miR-192 mediates TGF-beta/Smad3-driven renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Smad3-mediated upregulation of miR-21 promotes renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2011.05663.X

10.1111/J.1440-1681.2011.05663.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22211842%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference